Mark Steven Davis
Known title: DirectorCIK: 0002024613
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Transaction History
| YEXT | ▲ Buy | Option Exercise | 27,131 | — | 6/11/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 24,148 | $0 | 6/5/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 22,816 | $0 | 12/10/2024 | View on chart |
| YEXT | ▲ Buy | Grant | 62,500 | $0 | 6/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Yext Board Approves Long-Term Equity Award for CEO
Yext's board of directors has approved a long-term performance-based equity award for the company's CEO. This corporate governance move aligns executive compensation with long-term shareholder interests. The stock is currently trading near the upper end of its 52-week range, with an RSI of 68.5 suggesting recent momentum.
Yext Board Approves Long-Term Equity Award for CEO. Yext's board of directors has approved a long-term performance-based equity award for the company's CEO. This corporate governance move aligns executive compensation with long-term shareholder interests. The stock is currently trading near the upper end of its 52-week range, with an RSI of 68.5 suggesting recent momentum.